Infectex Announces Positive Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis

Infectex Ltd., a Russian portfolio company of Maxwell Biotech Venture Fund (MBVF), today announced positive results of a Phase 2b-3 clinical study of SQ109 added to the standard drug therapy regimen in patients with multidrug-resistant pulmonary tuberculosis (MDR-TB). SQ109 is a new small molecule drug discovered by scientists at Sequella, Inc. (USA) and the US […]

Infectex Announces Preliminary Phase 2b-3 Clinical Trial Results of SQ109 for the Treatment of Multidrug-Resistant Pulmonary Tuberculosis

The results were presented by principal investigator Prof. S.E.Borisov in his report “Effectiveness and safety of new anti-tuberculosis product SQ109” in Scientific and Practical Conference “Innovation Technologies in Phthisiology” (Moscow,  November 24, 2016). Results presented in the report demonstrate satisfactory profile of safety and tolerability of SQ109 as well as the increase in effectiveness of […]